Cargando…

Discovery of potent histone deacetylase inhibitors with modified phenanthridine caps

In discovery of novel HDAC inhibitory with anticancer potency, pharmacophores of phenanthridine were introduced to the structure of HDAC inhibitors. Fatty and aromatic linkers were evaluated for their solubility and activity. Both enzyme inhibitory and in vitro antiproliferative (against U937 cells)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, Wenli, Zhang, Lin, Wang, Xuejiang, Jia, Haiyong, Zhang, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7939570/ https://www.ncbi.nlm.nih.gov/pubmed/33663315 http://dx.doi.org/10.1080/14756366.2021.1892089

Ejemplares similares

Discovery of indole-3-butyric acid derivatives as potent histone deacetylase inhibitors
por: Chen, Yiming, et al.
Publicado: (2021)

Synthesis and Anticancer Activity Evaluation of Novel Phenanthridine Derivatives
por: Wan, Minghui, et al.
Publicado: (2019)

Discovery of N-(2-Aminophenyl)-4-(bis(2-chloroethyl)amino)Benzamide as a Potent Histone Deacetylase Inhibitor
por: Zhang, Lihui, et al.
Publicado: (2019)

Discovery and SAR analysis of 5-chloro-4-((substituted phenyl)amino)pyrimidine bearing histone deacetylase inhibitors
por: Zhang, Lin, et al.
Publicado: (2022)

Discovery of the First N-Hydroxycinnamamide-Based Histone Deacetylase 1/3 Dual Inhibitors with Potent Oral Antitumor Activity
por: Li, Xiaoyang, et al.
Publicado: (2014)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Discovery of 2-Phenylquinoline-4-Carboxylic Acid Derivatives as Novel Histone Deacetylase Inhibitors
por: Hui, Qian, et al.
Publicado: (2022)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

A novel histone deacetylase inhibitor, CKD5, has potent anti-cancer effects in glioblastoma
por: Choi, Seung Ah, et al.
Publicado: (2016)

Givinostat, a type II histone deacetylase inhibitor, induces potent caspase-dependent apoptosis in human lymphoblastic leukemia
por: Li, Ying, et al.
Publicado: (2016)

Thioester derivatives of the natural product psammaplin A as potent histone deacetylase inhibitors
por: Baud, Matthias G J, et al.
Publicado: (2013)

Zinc binding groups for histone deacetylase inhibitors
por: Zhang, Lei, et al.
Publicado: (2018)

“Golden” Cascade Cyclization to Benzo[c]‐Phenanthridines
por: Hendrich, Christoph M., et al.
Publicado: (2021)

Discovery of novel polysubstituted N-alkyl acridone analogues as histone deacetylase isoform-selective inhibitors for cancer therapy
por: Wang, Ze, et al.
Publicado: (2023)

The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma
por: Dias, Joana N.R., et al.
Publicado: (2018)

Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
por: Luo, Yuxiang, et al.
Publicado: (2020)

Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors
por: Ungerstedt, Johanna S.
Publicado: (2018)

Target Design of Novel Histone Deacetylase 6 Selective Inhibitors with 2-Mercaptoquinazolinone as the Cap Moiety
por: Bui, Hue Thi Buu, et al.
Publicado: (2022)

Dichloridobis(phenanthridine-κN)zinc(II)
por: Khoshtarkib, Zeinab, et al.
Publicado: (2009)

Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer
por: Alzoubi, Samer, et al.
Publicado: (2016)

A Novel Hydroxamic Acid-Based Curcumin Derivative as Potent Histone Deacetylase Inhibitor for the Treatment of Glioblastoma
por: Wang, Hao, et al.
Publicado: (2021)

The application of histone deacetylases inhibitors in glioblastoma
por: Chen, Rui, et al.
Publicado: (2020)

Inhibitors of human histone deacetylase with potent activity against the African trypanosome Trypanosoma brucei
por: Kelly, John M., et al.
Publicado: (2012)

Synthetic Routes and Biological Evaluation of Largazole and Its Analogues as Potent Histone Deacetylase Inhibitors
por: Li, Shang, et al.
Publicado: (2011)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Synthesis, Bacteriostatic and Anticancer Activity of Novel Phenanthridines Structurally Similar to Benzo[c]phenanthridine Alkaloids
por: Lasák, Pavel, et al.
Publicado: (2018)

Potential use of histone deacetylase inhibitors in cancer therapy
por: Gołąbek, Karolina, et al.
Publicado: (2015)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Discovery of Histone Deacetylase Inhibitor Using Molecular Modeling and Free Energy Calculations
por: Mishra, Abha, et al.
Publicado: (2022)

Novel nucleocapsid protein-targeting phenanthridine inhibitors of SARS-CoV-2
por: Wang, Yi-Ting, et al.
Publicado: (2022)

IRF5 is elevated in childhood-onset SLE and regulated by histone acetyltransferase and histone deacetylase inhibitors
por: Shu, Jin, et al.
Publicado: (2017)

Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia
por: Kong, Yi-Lin, et al.
Publicado: (2020)

The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects
por: West, Alison C., et al.
Publicado: (2012)

Borinostats: solid-phase synthesis of carborane-capped histone deacetylase inhibitors with a tailor-made selectivity profile
por: Selg, Christoph, et al.
Publicado: (2021)

Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria
por: Potluri, Vijay, et al.
Publicado: (2020)

Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy
por: Valdez, Benigno C., et al.
Publicado: (2016)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

Clinical Toxicities of Histone Deacetylase Inhibitors
por: Subramanian, Srividya, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_jqsrtsc0m85su93t2bna2eilv0